We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Zhu et al. report that non-vitamin K antagonist oral anticoagulant (NOAC) use was associated with modestly slower cognitive decline than warfarin or no anticoagulation among patients with atrial fibrillation (AF) and Alzheimer's disease (AD). This potentially important observation, however, depends critically on how death was handled in the longitudinal cognitive analysis.”
“Reweighting for death can address selection under strong assumptions, but it does not by itself resolve the conceptual problem that the cognitive outcome ceases to exist after death; the resulting slope therefore requires a more cautious interpretation than a treatment-associated slowing of AD progression.”
“Until robustness to this terminal event is demonstrated, these data strengthen the clinical case for NOACs on established thromboembolic and safety grounds, but should not yet be interpreted as evidence of a disease-modifying cognitive effect in AD.”
No takes yet. Share an insight, caveat, or question.
Paschalis Karakasis (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: